US · PHIO
Phio Pharmaceuticals Corp.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Marlborough, MA 01752
- Website
- phiopharma.com
Price · as of 2024-12-31
$1.14
Market cap 12.27M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $3,564,000.00 | ||||
| 2013 | $3,564,000.00 | $2,477,410.65 | $29,711,891,982.92 | $0.00 | $0.00 |
| 2014 | $683,100.00 | $1,281,777.15 | $0.00 | $0.00 | $16,783,316.81 |
| 2015 | $166,320.00 | $270,967.99 | $0.00 | $0.00 | $3,888,628.63 |
| 2016 | $46,926.00 | $21,786.86 | $17,174.29 | $0.00 | $2,707,335.45 |
| 2017 | $25,542.00 | $45,139.10 | $0.00 | $0.00 | $392,188.53 |
| 2018 | $2,197.80 | $185,605.39 | $27,285,465.75 | $0.00 | $0.00 |
| 2019 | $329.40 | $877.56 | $0.00 | $0.00 | $152,526.53 |
| 2020 | $340.20 | $138.33 | |||
| 2021 | $83.16 | ||||
| 2022 | $49.74 | ||||
| 2023 | $8.35 | ||||
| 2024 | $1.30 |
AI valuation
Our deep-learning model estimates Phio Pharmaceuticals Corp.'s (PHIO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.14
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PHIO | Phio Pharmaceuticals Corp… | $1.14 | 12.27M | — | — | — | — | -0.14 | 0.22 | — | 0.59 | — | 0.22 | 0.00% | — | — | -114.83% | 1067.49% | -94.69% | 0.00 | — | 5.65 | 5.30 | 0.73 | -9805.00% | — | -3386.00% | -694.83% | -7.01 | 1027.89% | 0.00% | 0.00% | 0.10% | 0.59 | 0.61 | — | -38.36 |
| ACXP | Acurx Pharmaceuticals, In… | $1.50 | 2.38M | — | — | — | — | -0.55 | 12.65 | — | — | — | 12.65 | 0.00% | — | — | -534.03% | 478.14% | -243.85% | 0.00 | — | 1.19 | 1.16 | — | -2355.00% | — | 594.00% | -133.41% | -3.20 | 352.03% | 0.00% | 0.00% | 0.00% | -0.29 | -0.39 | — | -34.86 |
| APRE | Aprea Therapeutics, Inc. | $0.92 | 6.41M | +3,789% | +73% | — | — | -0.99 | 0.66 | 8.54 | 0.70 | — | 0.66 | -523.16% | -953.00% | -862.43% | -68.98% | 415.99% | -55.58% | 0.00 | — | 7.01 | 6.80 | 1.60 | -4051.00% | 15763.00% | 1061.00% | -105.72% | -4.03 | 394.27% | 0.00% | 0.00% | 9.68% | 0.70 | 0.74 | -6.66 | -17.99 |
| APVO | Aptevo Therapeutics Inc. | $7.32 | 6.85M | — | — | — | — | -0.03 | 0.15 | — | 0.14 | — | 0.15 | 0.00% | — | — | -284.28% | -3555.20% | -119.36% | 0.97 | — | 1.72 | 1.40 | 0.17 | -9623.00% | — | 10277.00% | -3391.13% | -3.83 | -3437.14% | 0.00% | 0.00% | 0.00% | 0.14 | 0.14 | — | -27.06 |
| BCDA | BioCardia, Inc. | $1.29 | 7.48M | +6,369% | -19% | — | +16,927% | -0.90 | 8.59 | 123.95 | -0.73 | — | 8.59 | -7463.79% | -13794.83% | -13700.00% | 2074.67% | 810.64% | -236.81% | 1.14 | — | 1.13 | 1.02 | 0.18 | -6459.00% | -8784.00% | -1957.00% | -111.72% | -3.46 | 813.78% | 0.00% | 0.00% | 22.70% | -0.72 | -0.72 | 99.47 | -65.68 |
| CELZ | Creative Medical Technolo… | $1.81 | 4.67M | +18,729% | +39% | — | — | -1.12 | 0.97 | 558.52 | -0.04 | — | 1.06 | 60.00% | -52216.92% | -49940.74% | -65.85% | -1515.86% | -63.20% | 0.00 | — | 18.73 | 18.13 | 1.05 | -133.00% | 2222.00% | -3478.00% | -86.29% | -16.18 | -1399.06% | 0.00% | 0.00% | 43.11% | -0.04 | -0.04 | 18.49 | -4.10 |
| GLTO | Galecto, Inc. | $29.58 | 47.25M | — | — | — | — | -0.22 | 0.30 | — | 0.45 | — | 0.30 | 0.00% | — | — | -89.03% | -3844.56% | -77.45% | 0.00 | — | 14.07 | 12.58 | 0.67 | -4864.00% | — | -4955.00% | -396.40% | -15.56 | -3216.41% | 0.00% | 0.00% | 0.00% | 0.42 | 0.50 | — | -23.70 |
| INAB | IN8bio, Inc. | $1.70 | 7.88M | — | — | — | — | -13.04 | 27.41 | — | -14.50 | — | 27.41 | 0.00% | — | — | -154.44% | -359.44% | -111.38% | 0.35 | — | 4.08 | 3.61 | 0.23 | -4300.00% | — | 131.00% | -6.11% | -7.83 | -286.41% | 0.00% | 0.00% | 0.00% | -12.84 | -16.11 | — | 24.43 |
| KPRX | Kiora Pharmaceuticals, In… | $2.09 | 7.69M | — | +228% | +440% | — | 3.50 | 0.49 | 0.79 | -2.48 | — | 0.49 | 100.00% | 28.19% | 22.47% | 22.56% | 205.59% | 14.32% | 0.00 | 210.31 | 4.94 | 4.56 | -0.66 | -10359.00% | — | -18949.00% | 67.95% | 1.42 | 613.83% | 0.00% | 0.00% | 11.02% | -3.14 | -1.65 | -0.88 | -3.17 |
| MRKR | Marker Therapeutics, Inc. | $1.48 | 15.98M | +3,230% | -2% | — | — | -1.26 | 0.73 | 2.04 | 0.51 | — | 0.73 | -104.33% | -168.69% | -162.82% | -65.81% | 1313.50% | -54.82% | 0.00 | — | 6.36 | 6.22 | 1.73 | -3834.00% | 9906.00% | -3364.00% | -81.00% | -3.15 | 1288.92% | 0.00% | 0.00% | 30.30% | 0.51 | 0.52 | -0.87 | -26.44 |
| RNAZ | TransCode Therapeutics, I… | $9.61 | 8.81M | — | — | — | — | -0.93 | -7.75 | — | -0.61 | — | -7.75 | 0.00% | — | — | 8866.96% | 369.89% | -268.85% | -0.02 | -584.07 | 2.56 | 2.10 | 0.36 | -9864.00% | — | -2624.00% | -85.33% | -4.81 | 315.50% | 0.00% | 0.00% | 22.07% | -0.63 | -0.74 | — | -17.50 |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
- CEO
- Robert J. Bitterman
- Employees
- 5
- Beta
- 0.94
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.14) − 1 = — (DCF, example).